Literature DB >> 2129645

Tripotassium dicitrato bismuthate enemas in the treatment of ulcerative proctitis.

E D Srivastava1, G L Swift, S Wilkinson, G T Williams, B K Evans, J Rhodes.   

Abstract

Eleven patients with active proctitis or proctosigmoiditis completed one month's treatment with tripotassium dicitrato bismuthate enemas administered at night. Symptoms, sigmoidoscopic appearances, and the histological grade of acute inflammation were assessed at the commencement of therapy and after one month. An overall score of these features showed improvement in 9 of 11 patients, which encourages further investigation of bismuth in controlled trials for patients with inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2129645     DOI: 10.1111/j.1365-2036.1990.tb00505.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  4 in total

1.  Therapeutic role for bismuth compounds in TNBS-induced colitis in the rat.

Authors:  T C Peterson; C E Cleary; A M Shaw; D A Malatjalian; S J Veldhuyzen van Zanten
Journal:  Dig Dis Sci       Date:  2000-03       Impact factor: 3.199

2.  Chemical structure of bismuth compounds determines their gastric ulcer healing efficacy and anti-Helicobacter pylori activity.

Authors:  G S Sandha; R LeBlanc; S J Van Zanten; T D Sitland; L Agocs; N Burford; L Best; D Mahoney; P Hoffman; D J Leddin
Journal:  Dig Dis Sci       Date:  1998-12       Impact factor: 3.199

Review 3.  New developments in the pharmacotherapy of inflammatory bowel disease.

Authors:  J W Harting
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

4.  Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial.

Authors:  R D Pullan; S Ganesh; V Mani; J Morris; B K Evans; G T Williams; J Rhodes
Journal:  Gut       Date:  1993-05       Impact factor: 23.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.